-
Patent Agency Ranking
![METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS](/abs-image/US/2017/05/04/US20170119745A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170119745A1
公开(公告)日：2017-05-04
申请号：US15173506
申请日：2016-06-03
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Daniel C. Adelman , Jeffrey A. Silverman , Glenn Michelson , Caroline Dame Scatena
IPC: A61K31/4375 , A61K31/7068
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/7068 , C07D417/14 , A61K2300/00
Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
-
![METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS](/abs-image/US/2015/09/10/US20150250775A1/abs.jpg.150x150.jpg)
2.发明申请METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS 有权使用（+） - 1,4-二氢-7 - [（3S，4S）-3-甲氧基-4-（甲基氨基）-1-吡咯烷基] -4-氧代-1-（2-噻唑烷基）-1 ，8-萘基-3-羧酸用于治疗遗传性血液病公开(公告)号：US20150250775A1
公开(公告)日：2015-09-10
申请号：US14517535
申请日：2014-10-17
Applicant: SUNESIS PHARMACEUTICALS, INC.
Inventor： Glenn Michelson
IPC: A61K31/4375 , A61K38/19 , A61K39/395 , A61K38/18 , A61K31/7068 , A61K31/706
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/706 , A61K31/7068 , A61K38/18 , A61K38/19 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07D471/04 , A61K2300/00
Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
Abstract translation: 公开了治疗，预防或治疗先天性血液病的方法，例如骨髓增生异常综合征，包括慢性骨髓单核细胞白血病。 这些方法包括SNS-595的管理。 还提供了使用化合物与化疗，放射治疗，激素治疗，生物治疗或免疫治疗的治疗方法。 在某些实施方案中，治疗方法包括与阿糖胞苷组合施用SNS-595。 还公开了适用于该方法的药物组合物和单一单位剂型。
-
![Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders](/abs-image/US/2017/08/08/US09724338B2/abs.jpg.150x150.jpg)
公开(公告)号：US09724338B2
公开(公告)日：2017-08-08
申请号：US14517535
申请日：2014-10-17
Applicant: SUNESIS PHARMACEUTICALS, INC.
Inventor： Glenn Michelson
IPC: A61K31/4375 , A61K31/7068 , A61K31/513 , A61K45/06 , C07D471/04 , A61K31/706 , A61K38/18 , A61K38/19 , A61K39/395 , A61K39/00
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/706 , A61K31/7068 , A61K38/18 , A61K38/19 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07D471/04 , A61K2300/00
Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
-
![METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS](/abs-image/US/2015/07/09/US20150190380A1/abs.jpg.150x150.jpg)
4.发明申请METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS 审中-公开使用（+） - 1,4-二氢-7 - [（3S，4S）-3-甲氧基-4-（甲基氨基）-1-吡咯烷基] -4-氧代-1-（2-噻唑烷基）-1 ，8-萘基-3-羧酸用于治疗某些病理性疾病公开(公告)号：US20150190380A1
公开(公告)日：2015-07-09
申请号：US14461271
申请日：2014-08-15
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Daniel C. Adelman , Jeffrey A. Silverman , Glenn Michelson , Caroline Dame Scatena
IPC: A61K31/4375 , C07D417/14
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/7068 , C07D417/14 , A61K2300/00
Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
Abstract translation: 公开了治疗，预防或治疗血液系统疾病如白血病的方法。 这些方法包括SNS-595的管理。 还提供了使用化合物与化疗，放射治疗，激素治疗，生物治疗或免疫治疗的治疗方法。 在某些实施方案中，治疗方法包括与Ara-C组合施用SNS-595。 还公开了适用于该方法的药物组合物和单一单位剂型。
-
![METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS](/abs-image/US/2017/12/28/US20170368041A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170368041A1
公开(公告)日：2017-12-28
申请号：US15642195
申请日：2017-07-05
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Glenn Michelson
IPC: A61K31/4375 , A61K39/395 , A61K31/706 , A61K31/513 , A61K38/19 , A61K38/18 , A61K31/7068 , C07D471/04 , A61K45/06 , A61K39/00
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/706 , A61K31/7068 , A61K38/18 , A61K38/19 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07D471/04 , A61K2300/00
Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
-
-
-
-
Search Results
5
records
(took 0.014 seconds)
